Global Perspectives on Gastrointestinal Malignancies in 2021 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments in gastrointestinal malignancies.
Faculty Co-Chair
Gerald Prager, MD
Medical University of Vienna, Vienna, Austria
Faculty Co-Chair
Howard Hochster, MD, FACP
Rutgers Cancer Institute of New Jersey, Brunswick, NJ, USA
FACULTY MEMBERS
Dominik Modest, MD
Charité – Universitätsmedizin Berlin, Berlin, Germany
Eric Van Cutsem, MD, PhD
University of Leuven, Leuven, Belgium
Julien Taieb, MD, PhD
Université Paris Descartes, Paris, France
Teresa Macarulla, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Manish Shah, MD
Weill Cornell Medicine, New York, NY, USA
Tanios S. Bekaii-Saab, MD, FACP
Mayo Clinic Cancer Center, Phoenix, AZ
Efrat Dotan, MD
Fox Chase Cancer Center, Philadelphia, PA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Role of Immunotherapy and Targeted Agents in Gastroesophageal (GE) and Gastric Cancer
- Integration and Sequencing of New Agents in Hepatocellular Carcinoma (HCC)
- Treatment of Resectable Pancreatic Cancer and Metastatic Pancreatic Cancer
- New Therapeutic Options in Biliary Tract Cancer
- Metastatic Colorectal Cancer – Recent Insights and Future Approaches: Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments
- Metastatic Colorectal Cancer – Recent Insights in Immunotherapy
- Advances in Neoadjuvant Therapy for Rectal Cancer
